Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma^*

References

• Gabizon A.A., Barenholz Y., Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. 1993; 10(5)703–708
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54(4)987–992
   PubMed Web of Science ®Google Scholar
• Northfelt D.W., Martin F.J., Working P., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 1996; 36(1)55–63
   PubMed Web of Science ®Google Scholar
• Skubitz K.M., Hamdan H., Thompson R.C. A phase I study of ambulatory continuous infusion chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (ciCAD) for soft tissue sarcomas. J. Infus. Chemother. 1992; 2: 97–105
   Google Scholar
• Zalupski M., Metch B., Balcerzak S., et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J. Natl Cancer Inst. 1991; 83(13)926–932
   PubMed Web of Science ®Google Scholar
• Huang S.K., Mayhew E., Gilani S., Lasic D.D., Martin F.J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992; 52(24)6774–6781
   PubMed Web of Science ®Google Scholar
• Vaage J., Barbera Guillem, E., Abra R., Huang A., Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73(5)1478–1484
   PubMed Web of Science ®Google Scholar
• Northfelt D.W., Dezube B.J., Thommes J.A., et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1997; 15(2)653–659
   PubMed Web of Science ®Google Scholar
• Madhavan S., Northfelt D.W. Lack of vesicant injury following extravasation of liposomal doxorubicin [letter]. J. Natl. Cancer Inst. 1995; 87(20)1556–1557
   PubMed Web of Science ®Google Scholar
• Northfelt D.W. Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-related Kaposi's sarcoma (AIDS-KS) lesions than to normal skin. Proc. Am. Soc. Clin. Oncol. 1994; 13: 51, (abstract)
   Google Scholar
• Symon Z., Peyser A., Tzemach D., et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86(1)72–78
   PubMed Web of Science ®Google Scholar
• Uziely B., Jeffers S., Isacson R., et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995; 13(7)1777–1785
   PubMed Web of Science ®Google Scholar
• Skubitz K.M., Hamdan H., Thompson R.C., Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993; 72(10)2963–2969
   PubMed Web of Science ®Google Scholar
• Antman K., Crowley J., Balcerzak S.P., et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 1993; 11(7)1276–1285
   PubMed Web of Science ®Google Scholar
• Antman K., Crowley J., Balcerzak S.P., et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998; 82(7)1288–1295
   PubMed Web of Science ®Google Scholar
• Legha S.S., Benjamin R.S., Mackay B., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982; 96(2)133–139
   PubMed Web of Science ®Google Scholar
• Lokich J., Bothe A., Zipoli T., et al. Constant infusion schedule for adriamycin: a phase I–II clinical trial of a 30-day schedule by ambulatory pump delivery system. J. Clin. Oncol. 1983; 1(1)24–28
   PubMed Web of Science ®Google Scholar
• O'Bryan R.M., Baker L.H., Gottlieb J.E. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977; 39(5)1940–1948
   PubMed Web of Science ®Google Scholar
• Borden E.C., Amato D.A., Rosenbaum C., et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin. Oncol. 1987; 5(6)840–850
   PubMed Web of Science ®Google Scholar
• O'Bryan R.M., Luce J.K., Talley R.W., Gottlieb J.A., Baker L.H., Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973; 32(1)1–8
   PubMed Web of Science ®Google Scholar
• Gottlieb J.A., Benjamin R.S., Baker L.H., et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat. Rep. 1976; 60(2)199–203
   PubMedGoogle Scholar
• Bielack S.S., Erttmann R., Wrinkler K., Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur. J. Cancer Clin. Oncol. 1989; 25(5)873–882
   PubMedGoogle Scholar
• Blair S.C., Zalupski M.M., Baker L.H. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am. J. Clin. Oncol. 1994; 17(6)480–484
   PubMed Web of Science ®Google Scholar
• Kane M.J. Chemotherapy of advanced soft tissue and osteosarcomas. Semin. Oncol. 1989; 16(4)297–304
   PubMed Web of Science ®Google Scholar
• Samuels B.L., Vogelzang N.J., Ruane M., Simon M.A. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat. Rep. 1987; 71(10)971–972
   PubMedGoogle Scholar
• Schoenfeld D.A., Rosenbaum C., Horton J., Wolter J.M., Falkson G., DeConti R.C. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50(12)2757–2762
   PubMed Web of Science ®Google Scholar
• Patel S.R., Vadhan-Raj S., Burgess M.A., et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am. J. Clin. Oncol. 1998; 21(3)317–321
   PubMed Web of Science ®Google Scholar
• Le Cesne A., Judson I., Crowther D., et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 2000; 18(14)2676–2684
   PubMed Web of Science ®Google Scholar
• Leyvraz S., Bacchi M., Cerny T., et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK) [see comments]. Ann. Oncol. 1998; 9(8)877–884
   PubMed Web of Science ®Google Scholar
• Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group [see comments]. J. Clin. Oncol. 1995; 13(7)1537–1545
   PubMed Web of Science ®Google Scholar
• Dirix L.Y., Van Oosterom A.T. The role of ifosfamide in the treatment of sarcomas. Semin. Oncol. 1989; 116(1 Suppl. 3)39–45
   Google Scholar
• Bramwell V.H., Mouridsen H.T., Santoro A., et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur. J. Cancer Clin. Oncol. 1987; 23(3)311–321
   PubMedGoogle Scholar
• Bramwell V., Quirt I., Warr D., et al. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group—National Cancer Institute of Canada Clinical Trials Group. J. Natl. Cancer Inst. 1989; 81(19)1496–1499
   PubMed Web of Science ®Google Scholar
• Loehrer P.J., Sr., Sledge G.W., Jr., Nicaise C., et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J. Clin. Oncol. 1989; 7(11)1655–1659
   PubMed Web of Science ®Google Scholar
• Mansi J.L., Fisher C., Wiltshaw E., MacMillan S., King M., Stuart-Harris R. A phase I–II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur. J. Cancer Clin. Oncol. 1988; 24(9)1439–1443
   PubMedGoogle Scholar
• Yap B.S., Baker L.H., Sinkovics J.G., et al. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat. Rep. 1980; 64(1)93–98
   PubMedGoogle Scholar
• Judson I., Radford J.A., Harris M., et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2001; 37(7)870–877
   PubMed Web of Science ®Google Scholar
• Toma S., Tucci A., Villani G., Carteni G., Spadini N., Palumbo R. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res. 2000; 20(1B)485–491
   PubMed Web of Science ®Google Scholar
• Garcia A.A., Kempf R.A., Rogers M., Muggia F.M. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann. Oncol. 1998; 9(10)1131–1133
   PubMed Web of Science ®Google Scholar
• Chidiac T., Budd G.T., Pelley R., et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas [In Process Citation]. Invest. New Drugs 2000; 18(3)253–259
   PubMed Web of Science ®Google Scholar
• Skubitz K.M., Skubitz A.P. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998; 9(1)45
   PubMed Web of Science ®Google Scholar